Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
Objectives This post-hoc analysis explored the impact of body mass index (BMI) on tofacitinib efficacy/safety in patients with active psoriatic arthritis (PsA).Methods Data were pooled from two phase 3 studies (NCT01877668; NCT01882439). Analyses included patients randomised to tofacitinib 5/10 mg...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-04-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/7/1/e001486.full |